NCT07869329Not yet recruiting
Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients
Predicting Radiation-induced Cardiac Disease With the Biomarker Serum Pro-N-Cadherin
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
The study will measure serum Pro-N-Cadherin and NT-proBNP (pro B-type natriuretic peptide) levels in adults with non-small cell lung cancer receiving hypofractionated radiation therapy and evaluate whether these biomarkers correlate with radiation dose to the heart, cardiac dysfunction, and adverse cardiac events. Participants will undergo blood collection and echocardiography over a two-year follow-up period.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 6 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Nov 2030
- Lead sponsor
- Duke University
- Diseases
- Lung cancer
- NCT number
- NCT07869329
What you commit to
- Study type: Interventional
- Planned participants: 50
- From Nov 2026 to the primary completion date, Nov 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Planning to receive concurrent or sequential chemotherapy or immunotherapy
- Prior radiation therapy to the chest that included more than a minimal dose to the heart (\> 1 Gy mean dose).
Who the study is looking for
- ≥ 18 years of age
- Histologic documentation or clinical suspicion of non-small cell lung cancer based on pathology or imaging.
- Location of disease must be either a central right-sided tumor (defined as tumors with a planning target volume within 2 cm of the primary airways) arising below the level of the heart or any left-sided tumor arising below the level of the heart.
- Planned to receive hypofractionated radiation therapy (4-18 Gy fractions to a total dose of 45-70 Gy)
- Planning the target volume that is at or below the most superior aspect of the heart.
- Willing and able to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Medical Center Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.